Tyrosine kinase inhibitors (TKI) have improved outcomes in EGFR-mutant non-small cell lung cancer (NSCLC), but unmet needs remain. Even with third-generation options, the majority of patients will eventually develop disease progression due to acquired resistance. Now, a growing understanding of the mechanisms of acquired resistance is paving the way for personalised management that may improve outcomes.
